Feasability Study on the Contribution of Guided Puncture With Echoendoscopy (APOGEE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01892501|
Recruitment Status : Unknown
Verified November 2016 by Institut Bergonié.
Recruitment status was: Recruiting
First Posted : July 4, 2013
Last Update Posted : October 2, 2017
Impact of screening nodes mediastinal by PET, at different times of the management of cancer disease, remain unclear.
Benefits of combined PET and puncture with echoendoscopy for the diagnosis subsequent therapeutic management should be evaluated in these different contexts.
We would like to demonstrate the clinical utility of this association to replace more invasive diagnostic procedures and to assess the impact of the puncture on a possible modification of the therapeutic management.
It is a single center prospective diagnostic assessment
|Condition or disease||Intervention/treatment||Phase|
|Hypermetabolic Lymphadenopathy Mediastinum Lower, Posterior and Middle, Detected by PET-CT With 18F-FDG (PET)||Procedure: Guided punction of mediastinal lymphadenopathy by echoendoscopy Device: PET scan||Not Applicable|
Main objective :
Assess the performance (in terms of sensitivity) of guided punction by echoendoscopy in the characterization of hypermetabolic mediastinal lymph nodes in PET, in a context of New cancer or cancer recurrence.
Conduct of the study :
When a patient has had a PET scan showing a hypermetabolic or mediastinal lymph nodes in the lower, middle or posterior, his case is presented in a multidisciplinary meeting (PCR # 1), with definition of diagnostic strategy:
Approved indication is achieve a biopsy surgically to have a histological documentation of mediastinal lymph nodes with obvious impact on treatment decisions.
We distinguish two groups of patients based on the feasibility of the surgical procedure:
- Group A biopsy is surgically feasible
Group B: biopsy by surgery can not be performed (against medical contraindications or anesthetics) at that moment, definition of therapeutic strategy that was decided in the absence of histological documentation:
- Surgery outset
- Chemotherapy or other oncological treatment
- Supports non-oncological if benign disease suspected
- No treatment.
EUS is performed by oesophageal for two patient groups for the two groups of patients (within a maximum period of six weeks after the PET scan), under general anesthesia and endoscopic control.
According the pathological findings, the therapeutic strategy is defined in a second PCR (PCR # 2), to assess the impact of the puncture:
- Surgery outset
- Chemotherapy or other oncological treatment
- Supports non-oncological when benign pathology documented
- No treatment
- Selecting another surgical diagnostic procedure (non-contributory income).
A patient monitoring will be conducted for 12 months. The clinical and radiological data carried over the standard of care of the patient will be collected. Achieving a thoracoabdominopelvien scanner (TAP) at 1 year to characterize the evolution of the disease marks the end of the study for the patient.
For the patients who have had a negative biopsy, monitoring will involve a scanner TAP 6 month and 12 month then consultation with the oncologist.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Feasibility Study on the Contribution of Guided Puncture With Echoendoscopy in Evaluation of Hypermetabolic Lymphadenopathy Mediastinum Lower, Rear and Middle, Detected in PET-CT to 18 FDG (PET)|
|Actual Study Start Date :||March 8, 2013|
|Estimated Primary Completion Date :||December 31, 2017|
|Estimated Study Completion Date :||December 31, 2018|
hypermetabolic mediastinal lymph nodes in PET,
hypermetabolic mediastinal lymph nodes in PET,in a context of New cancer or cancer recurrence.
Procedure: Guided punction of mediastinal lymphadenopathy by echoendoscopy
EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.
Pathological samples are taken :
3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken.
Device: PET scan
The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
- Sensitivity of EUS-guided puncture [ Time Frame: 12 months ]The primary endpoint is the performance of endoscopic ultrasound-guided puncture after detection of lymph nodes with PET. The performance of EUS guided biopsy will be evaluated in terms of sensitivity. In most cases, only one lymph node is taken and performance analysis will be done by patient and not by injury. The reference technique (gold standard) is followed for 12 months. Sensitivity is the rate of subjects with a diagnosis of malignancy (excluding the results atypical / suspicious or non-contributory) according the results of EUS among all subjects with a neoplastic disease by the gold reference.
- Negative predictive value [ Time Frame: 12 month ]The negative predictive value of EUS guided biopsy will be evaluated. It is the rate of subjects with a diagnosis of benign pathology according the gold standard among all subjects for wich EUS reveal a benign pathology (excluding atypical/suspects findings or non contributory)
- Impact of the management of patient [ Time Frame: 12 months ]
The impact will be assessed in two ways :
- The clinical utility (avoid more invasive procedure)
- Matching between therapeutic strategies RCP1/RCP2.
- Side effects [ Time Frame: 12 months ]In all cases the side effects associated with the implementation of the guided puncture EUS will be collected and classified according to the classification of surgical complications of Clavien-Dindo [P Clavien and al. Ann Surg 2009, 250: 187-96]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01892501
|Bordeaux, Grionde, France, 33076|
|Contact: Dominique Bechade 0558337871 D.Bechade@bordeaux.unicancer.fr|
|Contact: Simone Mathoulin-Pélissier, PU-PH 0558333398 S.Mathoulin@bordeaux.unicancer.fr|
|Principal Investigator: Bechade Dominique, Dr|